本研究旨在探索miR-223在急性淋巴细胞白血病(ALL)患儿血浆中的表达情况及其在不同疾病状态下的表达特点.选取北京儿童医院2005年5月至2012年1月住院ALL患儿64例,包括初诊患儿30例,缓解患儿30例,复发患儿4例.直接使用血浆进行逆转录和实时荧光定量PCR的方法检测样本中miR-223的表达情况.结果发现,miR-223在初诊患儿血浆中表达较低,在缓解患儿中表达升高.由于复发例数太少,暂未发现差异性；在初诊或缓解患儿中,miR-223在TEL-AML1阳性组和无融合基因B系ALL组表达均无明显差异.结论:miR-223在初诊患儿血浆中表达较低,在缓解患儿中表达明显升高,可能起着抑癌基因的作用,并可作为白血病的分子标志物以及监测疗效的指标.%This study was aimed to investigate the expression of plasma miR-223 in pediatric acute lymphoblastic leukemia (ALL) in different treatment time point. A total of 64 pediatric ALL samples were selected from patients treated in Beijing Children's Hospital from May 2005 to January 2012, including 30 samples at new diagnosis (ND), 30 samples at complete remission (CR) and 4 samples at relapse. Without RNA extraction, the miR-223 levels in plasma were directly detected by a reverse-transcription quantitative real-time PCR assay. The results indicated that the expression of plasma miR-223 in pediatric ALL was lower at ND but elevated after CR. The miR-223 expression in plasma of relapse patients didn't show significant difference probably due to a few cases of relapse. The miR-223 levels in plasma had not displayed significant difference between TEL-AML1 positive patients and no fusion gene B lineage ALL patients either at ND or at CR. It is concluded that the plasma miR-223 decreases at ND and increases in CR of children with ALL. miR-223 may act as an anti-oncogene and may be taken as a potential predictive biomarker for evaluating the therapeutic effect of leukemia.
展开▼
